Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy combo shows promise in shrinking lung tumors before surgery

NCT ID NCT05925530

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 10, 2026 · Updated 5 times

Summary

This phase 2 trial is testing whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery or radiation can help people with stage IIB-IIIB non-small cell lung cancer. The study includes 142 participants whose tumors are considered removable or borderline removable. After initial treatment, some will have surgery followed by more durvalumab, while others will get chemoradiation followed by durvalumab. The main goal is to see how many people can successfully have their tumors surgically removed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
durvalumab (an immunotherapy drug) plus platinum-based chemotherapy
What this could lead to
If successful, this approach could improve the chances of completely removing lung cancer tumors and help keep the cancer from coming back.
What could go wrong
This is a mid-stage trial with only 142 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of the lungs or other organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

142 people

The number who actually took part.

Started

Feb 2024

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Deemed resectable or borderline resectable at baseline, confirmed by MDT evaluation at diagnosis. * Previously untreated and pathologically confirmed Stage IIB to select \[i.e.N2\] Stage IIIB by AJCC v8. * Nodal status confirmed with whole body FDG-PET and biopsy via endobronchial ultrasound, mediastinoscopy, or thoracoscopy. * Mandatory brain MRI. * EGFR and ALK wild-type. * Medically operable: adequate cardiac and lung function to undergo resection. * Participant must be ≥ 18 years, at the time of screening. * Histologically or cytologically documented NSCLC. * Minimum life expectancy of 12 weeks. * Minimum body weight of 30 kg. * Male and female participants must be willing to use acceptable methods of contraception. * Female participants of childbearing potential must have negative pregnancy test. Exclusion Criteria: * Unresectable NSCLC confirmed by MDT evaluation at baseline * Stage IIIC patients * Participants whose planned surgery at enrollment is a wedge resection * Known EGFR mutation or ALK translocation * Participants contraindicated for surgical intervention due to comorbid conditions * Participants who are allergic to study intervention. * Participants with more than one primary tumour. * Known active hepatitis infection, positive HCV antibody, HBsAg or HBV core antibody (anti-HBc), at screening. * Female participants who are pregnant or breastfeeding. * Judgement by the investigator that the participant should not participate in the study. * Previously infected or tested positive for human immunodeficiency virus.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Research Site

    The Bronx, New York, 10467, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Charlottesville, Virginia, 22908, United States

  • Research Site

    Vienna, 1130, Austria

  • Research Site

    Vienna, 1140, Austria

  • Research Site

    Kingston, Ontario, K7L 2V7, Canada

  • Research Site

    Chicoutimi, Quebec, G7H 5H6, Canada

  • Research Site

    Montreal, Quebec, H4A 3J1, Canada

  • Research Site

    Brno, 625 00, Czechia

  • Research Site

    Olomouc, 77900, Czechia

  • Research Site

    Prague, 12808, Czechia

  • Research Site

    Prague, 150 06, Czechia

  • Research Site

    La Tronche, 38700, France

  • Research Site

    Marseille, 13008, France

  • Research Site

    Montpellier, 34295, France

  • Research Site

    Mulhouse, 68070, France

  • Research Site

    Paris, 75005, France

  • Research Site

    Pessac, 33604, France

  • Research Site

    Poitiers, 86000, France

  • Research Site

    Toulouse, 31059, France

  • Research Site

    Berlin, 13125, Germany

  • Research Site

    Cologne, 51109, Germany

  • Research Site

    Großhansdorf, 22927, Germany

  • Research Site

    Moers, 47441, Germany

  • Research Site

    Würzburg, 97074, Germany

  • Research Site

    Budapest, 1122, Hungary

  • Research Site

    Törökbálint, 2045, Hungary

  • Research Site

    Bari, 70124, Italy

  • Research Site

    Bologna, 40138, Italy

  • Research Site

    Milan, 20132, Italy

  • Research Site

    Milan, 20133, Italy

  • Research Site

    Milan, 20141, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Palermo, 90127, Italy

  • Research Site

    Pavia, 27100, Italy

  • Research Site

    Peschiera del Garda, 37019, Italy

  • Research Site

    Lisbon, 1350-352, Portugal

  • Research Site

    Lisbon, 1500-650, Portugal

  • Research Site

    Barakaldo, 48903, Spain

  • Research Site

    Barcelona, 08025, Spain

  • Research Site

    L'Hospitalet de Llobregat, 08908, Spain

  • Research Site

    Madrid, 28007, Spain

  • Research Site

    Madrid, 28027, Spain

  • Research Site

    Madrid, 28046, Spain

  • Research Site

    Pamplona, 31008, Spain

  • Research Site

    Valencia, 46009, Spain

  • Research Site

    Zaragoza, 50009, Spain

  • Research Site

    Solna, 171 64, Sweden

  • Research Site

    Uppsala, SE-751 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.